Bayer lifts peak sales estimate for prostate cancer drug Nubeqa : Report
Frankfurt: A therapy mix including Bayer's Nubeqa drug was shown to significantly prolong the lives of men suffering from metastatic prostate cancer in a clinical study, prompting the drugmaker to boost sales estimates for the product.
Nubeqa, when combined with standard therapy, reduced the risk of dying during the trial period by 32.5% in a comparison to standard therapy alone, the German company said in a statement on Thursday, citing trial results.
The drug is one of three Bayer pharmaceuticals that the company expects to generate more than $1 billion in peak annual sales, known in the industry as blockbusters, alongside kidney disease treatment finerenone and menopausal symptoms relief elinzanetant.
The trial's overall success was announced in December and detailed results were published in The New England Journal of Medicine on Thursday.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.